The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis

Journal of Mammary Gland Biology and Neoplasia

Volumn 6, Issue 4, 2001, Pages 393-406

  Eccles, Suzanne A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Angiogenesis; Drug resistance; HER2 neu c erbB 2; Invasion; Metastasis; Signaling pathways

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; CANERTINIB; CISPLATIN; CURCUMIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EMODIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ETOPOSIDE; FLUOROURACIL; GELDANAMYCIN; MELPHALAN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEINASE; RETINOIC ACID; RIBOZYME; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TAMOXIFEN; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RESISTANCE; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE; CELL MIGRATION; CELL MOTILITY; CLINICAL TRIAL; CORRELATION FUNCTION; DNA REPAIR; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME RELEASE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; METASTASIS; NONHUMAN; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR CELL; TUMOR VASCULARIZATION; BREAST TUMOR; DISEASE COURSE; FEMALE; METABOLISM; PHYSIOLOGY; REVIEW;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 0035496541     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014730829872     Document Type: Article

References (69)

1. D. Harari and Y. Yarden (2000). Molecular mechanisms underlying Erb 2/HER2 action in breast cancer. Oncogene 19:6102-6114.
2. S. Sundaresan, E. Penuel, and M. Sliwkowski (1999). The biology of human epidermal growth factor receptor 2. Curr. Oncol. Rep. 1: 6-22.
3. Y. Yarden and M. X. Sliwkowski (2001). Untangling the erbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-137.
4. L. N. Klapper, M. H. Kirschbaum, M. Sela, and Y. Yarden (2000). Biochemical and clinical implications of the erbB/HER signalling network of growth factor receptors. Adv. Cancer Res. 77: 5-79.
5. B. P. Nicholson (2000). Ongoing and planned trials of hormonal therapy and trastuzumab. Semin. Oncol. 27:33-37.
6. D. Yu, J. Hamada, H. Zhand, G. L. Nicolson, and M. C. Hung (1992). Mechanisms of c-erbB-2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 7:2263-2270.
7. S. A. Eccles (2000). Cell biology of lymphatic metastasis: The potential role of c-erbB oncogene signalling. Recent Results Cancer Res. 157:41-54.
8. S. Ménard, E. Tagliabue, M. Campiglio, and S. Pupa (2000). Role of HER2 gene overexpression in breast carcinoma. J. Cell Physiol. 182:150-162.
9. F. Révillion, J. Bonneterre, and J. P. Peyrat (1998). ERBB2 oncogene in human breast cancer and its clinical significance. Eur J. Cancer 34:791-808.
10. A. D. Thor, S. Liu, S. Edgerton, D Moore II, K. M. Kasowitz, C. C. Benz, D. F. Stern, and M. P. DiGiovanna (2000). Activation (tyrosine phosphorylation) of erbB-2 (HER2/neu): A study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 18: 230-3239.
11. X. Ouyang, T. Gulliford, G. C. Huang, C. Harper-Wynne, S. Shousha, and R. J. Epstein (2001). Multisite phosphotyping of the erbB-2 oncoprotein in human breast cancer. Mol. Diagno. 6:17-25.
12. C. Sweeney and K. L. Carraway III (2000). Ligand discrimination by ErbB receptors: Differential signalling through differential phosphorylation site usage. Oncogene 19:5568-5573.
13. F. Gebhardt, K. S. Zanker, and B. Brandt (1998). Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases and bone marrow micrometastases from breast cancer patients. Biochem. Biophys. Res. Commun. 247:319-323.
14. M. A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga (2001). Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 61: 744-4749.
15. X. Jing, K. Kakudo, M. Murakami, Y. Nakamura, Y. Yokoi, Q. Yang, S. Oura, and T. Sakurai (1999). Intraductal spread of invasive breast carcinoma has a positive correlation with c-erbB-2 over-expression and vascular invasion. Cancer 86:439-448.
16. S. Braun, G. Schlimok, I. Heumos, G. Schaller, L. Riethdorf, G. Reithmuller, and K. Pantel (2001). erbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res. 61:1890-1895.
17. B. Brandt, A. Roetger, S. Heidl, C. Jackisch, R. J. Leffe, G. Assmann, and K. S. Zanker (1998). Isolation of blood-borne epithelium-derived c-erbB-2 protein-positive clustered cells from peripheral blood of breast cancer patients. Int. J. Cancer 76:824-828.
18. P. Uciechowski, C. Eder, B. Bockmann, B. Suchy, G. Driesel, S. Jackel, I. Kusiak, H.-J. Grill, and M. Geising (2000). Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Br. J. Cancer 83:1664-1673.
19. B. D'Souza and J. Taylor-Papadimitriou (1994). Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc. Natl. Acad. Sci. U.S.A. 91: 702-7706.
20. T. Shibata, A. Ochiai, Y. Kanai, S. Akimoto, M. Gotoh, N. Yasui, R. Machinami, and S. Hirohashi (1996). Dominant negative inhibition of the association between β-catenin and c-erbB-2 by N-terminally deleted β catenin suppresses the invasion and metastasis of cancer cells. Oncogene 13:883-889.
21. M. Tan, R. Grijalva, and D. Yu (1999). Heregulin β-1 activated phosphatidyl-inositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res. 59:1620-1625.
22. B. D'Souza, F. Berdichevsky, N. Kyprianou, and J. Taylor-Papadimitriou (1993). Collagen-induced morphogenesis and expression of the α2 integrin subunit is inhibited in c-erbB-2-transfected human mammary epithelial cells. Oncogene 8:1797-1806.
23. M. A. Adelsman, J. B. McCarthy, and Y. Shimizu (1999). Stimulation of β1-intgrin function by epidermal growth factor and heregulin β has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Mol. Biol. Cell 10:2861-2878.
24. K. M. Ignatoski, T. Maehama, S. M. Markwart, J. E. Dixon, D. L. Livant, and S. P. Ethier (2000). ErbB overexpression confers a PI3 kinase dependent invasion capacity on human mammary epithelial cells. Br. J. Cancer 82:666-674.
25. D. Gambaletta, A. Marchetti, L. Benedetti, A. M. Mercurio, A. Sacchi, and R. Falconi (2000). Co-operative signalling between α6β4 integrin and erbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion. J. Biol. Chem. 275:10604-10610.
26. neu. Mol. Carcinog. 25:150-154.
27. R. Vadlamudi, L. Adam, B. Tseng, L. Costa, and R. Kumar (1999). Transcriptional upregulation of paxillin expression by heregulin in human breast cancer cells. Cancer Res. 59:2843-2846.
28. neu-containing glycoprotein complex of a microfilament-associated signal transduction particle. J. Biol. Chem. 274:25651-25658.
29. M. Komatsu, S. Jepson, M. E. Arango, C. A. Carothers Caraway, and K. L. Carraway (2001). Muc4/sialomucin complex, an intramembrane modulator of erbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene 20:461-471.
30. D. Zhu and L. Bourguignon (1996). Overexpression of CD44 in p185neu transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid mediated membrane cytoskeleton interaction and cell adhesion. Oncogene 12:2309-2314.
31. F. J. Xu, S. Stack, C. Boyer, K. O'Briant, R. Whitaker, G. B. Mills, Y. H. Yu, and R. C. Bast (1997). Heregulin and agonist anti-p185 (c-erbB-2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185 (c-erbB2): Increased invasiveness may contribute to poor prognosis. Clin. Cancer Res. 3:1629-1634.
32. A. Roetger, A. Merschjann, T. Dittmar, C. Jackisch, A. Barnekow, and B. Brandt (1998). Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by us of an extravasation model. Am. J. Pathol. 153:1797-1806.
33. A. F. Chambers, G. N. Naumov, H. J. Varghese, K. V. Nadkarni, I. C. MacDonald, and A. C. Groom (2001). Critical steps in haematogenous metastasis: An overview. Surg. Oncol. Clin. N. Am. 10: 43-255.
34. A. Mazumdar, L. Adam, D. Boyd, and R. Kumar (2001). Heregulin regulation of urokinase plasminogen activator and its receptor: Human breast epithelial cell invasion. Cancer Res. 61:400-405.
35. D. Giunciuglio, M. Culty, G. Fassina, L. Masiello, A. Melchiori, G. Paglialunga, G. Arand, F. Ciardiello, F. Basolo, E. W. Thompson, and A. Albini (1995). Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int. J. Cancer 63:815-822.
36. M. Tan, J. Yao, and D. Yu (1997). Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57:1199-1205.
37. B. H. Brandt, A. Roetger, T. Dittmar, G. Nicolai, M. Seeling, A. Merschjann, J.-R. Nofer, G. Dehmer-Moller, R. Junker, G. Assmann, and K. H. Zaenker (1999). C-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J. 13:1939-1949.
38. L. Adam, R. Vadlamudi, S. B. Kondapaka, J. Chernoff, J. Mendelsohn, and R. Kumar (1998). Heregulin regulates cytoskeletal reorganisation and cell migration through the p21-activated kinase 1 via phosphatidylinositol-3 kinase. J. Biol. Chem. 273: 8238-28246.
39. A. Grothey, R. Hashizume, H. Ji, B. E. Tubb, C. W. Patrick, D. Yu, E. E. Mooney, and P. D. McCrea (2000). C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 19:4864-4875.
40. K. S. R. Spencer, D. Graus-Porta, J. Leng, N. E. Hynes, and R. L. Klemke (2000). erbB2 is necessary for induction of carcinoma cll invasion by erbB family receptor tyrosine kinases. J. Cell Biol. 148: 85-397.
41. V. S. Sivaraman, H. Wang, G. J. Nuova, and C. C. Malbon (1997). Hyper-expression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99:1478-1483.
42. S. Zrihan-Licht, Y. Fu, J. Settleman, K. Schinkmann, L. Shaw, I. Keydar, S. Avraham, and H. Avraham (2000). RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer invasion. Oncogene 19:1318-1328.
43. A. H. Talukder, L. Adam, A. Raz, and R. Kumar (2000). Heregulin regulation of autocrine motility factor expression in human tumor cells. Cancer Res. 60:474-480.
44. R. Bagheri-Yarmand, R. K. Vadlamudi, R.-A. Wang, J. Mendelsohn, and R. Kumar (2000). Vascular endothelial growth factor upregulation via p21-activated kinase-1 signalling regulates heregulin-β1-mediated angiogenesis. J. Biol. Chem. 275:39451-39457.
45. S. Xiong, R. Grijalva, L. Zhang, N. T. Nguyen, P. W. Pisters, R. E. Pollock, and D. Yu (2001). Upregulation of vascular endothelial growth factor in breast cancer cells by the heregulin-β1-activated p38 signalling pathway enhances endothelial cell migration. Cancer Res. 61:1727-1732.
46. A. Petit, J. Rak, W. C. Hung, P. Rockwell, N. Goldstein, B. Fendly, and R. S. Kerbel (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151:1523-1531.
47. W. B. Carter and M. D. Ward (2000). HER2 regulatory control of angiopoietin-2 in breast cancer. Surgery 128:153-158.
48. W. B. Carter, J. B. Hoying, C. Boswell, and S. K. Williams (2001). HER2/NEU overexpression induces endothelial cell retraction. Int. J. Cancer 91:295-299.
49. R. Mass (2000). The role of HER-2 expression in predicting response to therapy in breast cancer. Semin. Oncol. 27: 46-52.
50. D. Yu and M.-C. Hung (2000). Role of erbB2 in breast cancer chemosensitivity. Bioessays 22:673-680.
51. H. B. Burke, A. Hoang, J. D. Iglehart, and J. R. Marks (1998). Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 82:874-877.
52. S. De Placido, C. Carlomagno, M. De Laurentis, and A. R. Bianco (1998). c-erbB-2 predicts tamoxifen efficacy in breast cancer patients Breast Cancer Res. Treat. 52:55-64.
53. A. Jukkola, R. Bloigu, E.-R. Savolainen, K. Holli, and G. Blanco (2001). c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur. J. Cancer 37:347-354.
54. R. Colomer, S. Montero, A. Lluch, B. Ojeda, A. Barnadas, A. Casado, B. Massuti, H. Cortes-Funes, and B. Lloveras (2000). Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin. Cancer. Res. 6:2356-2362.
55. L. N. Harris, L. Yang, C. Tang, D. Yang, and R. Lupu (2000). Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin β-2. Clin. Cancer Res. 4: 005-1012.
56. S. Sleijfer, J. G. W. Asschert, H. Timmer-Bosscha, and N. H. Mulder (1998). Enhanced sensitivity to tumor necrosis factor a in doxorubicin resistant tumor cell lines due to down-regulated c-erbB-2. Int. J. Cancer 77:101-106.
57. cdc2 kinase. Mol. Cell 2:581-591.
58. M. D. Pegram, R. S. Finn, K. Arzoo, M. Beryt, R. J. Pietras, and D. J. Slamon (1997). The effect of HER2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-557.
59. M. A. Alaoui-Jamali, J. Paterson, A.-E. Al Moustafa, and L. Yen. (1997). The role of erbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: Mechanisms and implications. Biochem. Cell Biol. 75:315-325.
60. Y. Liu, D. El-Ashry, D. Chen, I. F. Y. Ding, and F. G. Kern (1995). MCF-7 breast cancer cells overexpressing transfected c-erbB2 have an in vitro growth advantage in estrogen-depleted conditions and a reduced estrogen-dependence and tamoxifen sensitivity in vivo. Breast Cancer Res. Treat. 34:97-117.
61. H. Kurokawa, A. E. G. Lenferink, J. F. Simpson, P. I. Pisacane, M. X. Sliwkowski, J. T. Forbes, and C. L. Arteaga (2000). Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER-2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 60:5887-5894.
62. D. Yu and M.-C. Hung (2000). Overexpression of erbB2 in cacer and erbB2-targeting strategies. Oncogene 19:6115-6121.
63. C. I. Sartor (2000). Biological modifiers as potential radiosensitizers: Targeting the epidermal growth factor receptor family. Semin. Oncol. 27:15-20.
64. G. S. Rao, S. Murray, and S. P. Ethier (2000). Radiosensitization of human breast cancer cells by a novel erbB family receptor tyrosine kinase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 48:1519-1528.
65. M. De Bortoli and C. Dati (1997). Hormonal regulation of type 1 receptor tyrosine kinase expression in the mammary gland. J. Mammary Gland Biol. Neoplasia 2:175-185.
66. R. J. Pietras, J. Arboleda, D. M. Reese, N. Wongvipat, M. Pegram, L. Ramos, C. M. Gorman, M. G. Parker, M. X. Sliwkowski, and D. J. Slamon (1995). HER-2 tyrosine kinase pathway targets estrogen receptors and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446.
67. M. E. Balana, R. Lupu, L. Labriola, E. H. Charreau, and P. V. Elizalde (1999). Interactions between progestins and heregulin (HRG) signalling pathways: HRG acts as a mediator of progestins proliferative effects in mouse mammary adenocarcinoma. Oncogene 18:6370-6379.
68. S. A. Eccles, W. J. Court, G. A. Box, C. J. Dean, R. G. Melton, and C. J. Springer (1999). Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res. 54:5171-5177.
69. S. A. Eccles (1998). c-erbB-2 as a target for immunotherapy. Exp. Opinion Invest. Drugs. 7:1879-1896.